<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Zoom Lymphatic Seminar on Michael’s Domain</title><link>https://jeltsch.org/en/tags/zoom-lymphatic-seminar/</link><description>Recent content in Zoom Lymphatic Seminar on Michael’s Domain</description><generator>Hugo</generator><language>en-us</language><copyright>Copyright © 2002 - 2026 Michael Jeltsch.</copyright><lastBuildDate>Fri, 24 Jul 2026 00:18:18 +0300</lastBuildDate><atom:link href="https://jeltsch.org/en/tags/zoom-lymphatic-seminar/index.xml" rel="self" type="application/rss+xml"/><item><title>Making the cut: Why VEGF-C != VEGF-C</title><link>https://jeltsch.org/en/making_the_cut_why_vegf_c_vegf_c/</link><pubDate>Wed, 28 Sep 2022 00:00:00 +0000</pubDate><guid>https://jeltsch.org/en/making_the_cut_why_vegf_c_vegf_c/</guid><description>&lt;p&gt;Yesterday, I talked about VEGF-C in the Zoom Lymphatic Seminar series, which is organized by 
 &lt;a href="https://profiles.sc-ctsi.org/young-kwon.hong" target="_blank" rel="noopener noreferrer nofollow"&gt;Young Kwon Hong&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
. Since there was not much time to ask questions, I am happy to answer them via email. If you have missed the link to the presentation slides, here it is: 
 &lt;a href="https://mjlab.fi/c" target="_blank" rel="noopener noreferrer nofollow"&gt;https://mjlab.fi/c&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
. The take-home message: Many different mature forms of VEGF-C can be generated from pro-VEGF-C by proteolytic processing (and the same is true for VEGF-D). These forms behave VERY differently from each other. The extreme case is activation by Cathepsin D (CTSD): When activated by CTSD, VEGF-C becomes almost exclusively lymphangiogenic, while after activation by the same protease, VEGF-D becomes exclusively angiogenic. The detection of CTSD-activated VEGF-C is difficult because all well-functioning antibodies recognize epitopes N-terminal to the cleavage site (or they straddle the cleavage site). The second talk was by 
 &lt;a href="https://www.i2mc.inserm.fr/en/equipe-barbara-garmy-susini-anne-catherine-prats-2/" target="_blank" rel="noopener noreferrer nofollow"&gt;Barbara Garmy-Susini&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
, and her topic was a nice fit since she talked about using VEGF-C in the therapy of lymphedema. But as we know already from VEGF-A, vascular growth factors alone might be not sufficient to generate a functional vasculature…&lt;/p&gt;</description></item></channel></rss>